Horizon BCBSNJ Uniform Medical Policy Manual Policy Number: 115 Effective Date: 01/01/2017

Size: px
Start display at page:

Download "Horizon BCBSNJ Uniform Medical Policy Manual Policy Number: 115 Effective Date: 01/01/2017"

Transcription

1 Horizon BCBSNJ Uniform Medical Policy Manual Section: Surgery Policy Number: 115 Effective Date: 01/01/2017 Original Policy Date: 05/25/2010 Last Review Date: 05/10/2016 Date Published to Web: 06/23/2010 Subject: Gender Reassignment Surgery Description: IMPORTANT NOTE: The purpose of this policy is to provide general information applicable to the administration of health benefits that Horizon Blue Cross Blue Shield of New Jersey and Horizon Healthcare of New Jersey, Inc. (collectively Horizon BCBSNJ ) insures or administers. If the member s contract benefits differ from the medical policy, the contract prevails. Although a service, supply or procedure may be medically necessary, it may be subject to limitations and/or exclusions under a member s benefit plan. If a service, supply or procedure is not covered and the member proceeds to obtain the service, supply or procedure, the member may be responsible for the cost. Decisions regarding treatment and treatment plans are the responsibility of the physician. This policy is not intended to direct the course of clinical care a physician provides to a member, and it does not replace a physician s independent professional clinical judgment or duty to exercise special knowledge and skill in the treatment of Horizon BCBSNJ members. Horizon BCBSNJ is not responsible for, does not provide, and does not hold itself out as a provider of medical care. The physician remains responsible for the quality and type of health care services provided to a Horizon BCBSNJ member. Horizon BCBSNJ medical policies do not constitute medical advice, authorization, certification, approval, explanation of benefits, offer of coverage, contract or guarantee of payment. Gender dysphoria, previously known as gender identity disorder, is a condition in which a person feels a strong and persistent identification with the opposite gender accompanied with a severe sense of discomfort in their own gender. People with gender dysphoria often report a feeling of being born the wrong sex or "trapped in the wrong body". Gender dysphoria is broadly defined as a discomfort or distress that is caused by a discrepancy between a person's gender identity and that person's sex assigned at birth (and the associated gender role and/or primary and secondary sex characteristics). 8 The diagnosis of gender dysphoria can be established at childhood, adolescence, or adulthood. People who wish to change their sex may be referred to as "transsexuals". In May 2013, the American Psychiatric Association published an update to their Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). This update included a significant change to the nomenclature of conditions related to gender psychology. Specifically,

2 the term "Gender Identity Disorder (GID)" was replaced with "Gender Dysphoria". 8 Additionally, the DSM-5 provided updated diagnostic criteria for gender dysphoria for both children and adults. However, ICD-9 and ICD-10 codes continue to use the term gender identity disorder. Due to the far-reaching and irreversible results of hormonal and/or surgical transformational measures, a step-wise approach to therapy for GID, including accurate diagnosis and long-term treatment by a multidisciplinary team including behavioral, medical and surgical specialists, is vital to the patient's best interest. As with any treatment involving psychiatric disorders, a thorough behavioral analysis by a qualified practitioner is needed. After the diagnosis of gender dysphoria is made, the therapeutic approach to gender dysphoria usually includes three elements or phases (sometimes labeled triadic therapy): hormones of the desired gender, a real-life experience in the desired role, and surgery to change the genitalia and other sex characteristics. The most typical order, if all three elements are undertaken, is hormones followed by real-life experience and, finally surgery to change the genitalia and other sex characteristics. However, the diagnosis of gender dysphoria invites the consideration of a variety of therapeutic options, only one of which is the complete therapeutic triad. Clinicians have become increasingly aware that not all persons with gender dysphoria need or want all three elements of triadic therapy. Hormone therapy is administered under medical supervision and is important in the gender transition process by altering body hair, breast size, skin appearance and texture, body fat distribution, and the size and function of sex organs. Additionally, real-life experience is important to validate the individual's desire and ability to incorporate into their desired gender role within their social network and daily environment. This generally involves gender-specific appearance (garments, hairstyle, etc.), involvement in various activities in the desired gender role including work and academic settings, legal acquisition of a gender appropriate first name, and acknowledgement by others of their new gender role. Gender reassignment surgery is one treatment option for extreme cases of gender dysphoria. Gender reassignment surgery is not a single procedure, but part of a complex process involving multiple medical, psychiatric, and surgical specialists working in conjunction with each other and the individual to achieve successful behavioral and medical outcomes. Before undertaking gender reassignment surgery, important medical and psychological evaluations, medical therapies and behavioral trials are undertaken to confirm that surgery is the most appropriate treatment choice for the individual Surgical treatment differs depending upon the original physical gender of the individual. For male-to-female patients, also known as " transwomen", surgery involves removal of the testicles and penis and the creation of a pseudo vagina, clitoris, and labia. For female-to-male patients, also known as "transmen", surgery involves removal of the uterus, ovaries, and vagina, and creation of a neophallus, and scrotum with scrotal prostheses. Additional surgical procedures may also be performed to improve the gender appropriate appearance of the individual. These include, but are not limited to, breast augmentation, liposuction, Adam's apple reduction, voice modification surgery (vocal cord shortening), rhinoplasty, facial reconstruction (facial bone reduction, jaw shortening, sculpturing), lip reduction, and chin implants.

3 Policy: I. Contract exclusions and/or limitations for gender reassignment surgery, including related services such as medical counseling, psychological clearance for surgery in the absence of a need for behavioral health therapeutic services, and hormonal therapy, will determine the available benefit for gender reassignment surgery. II. For contracts that specify gender reassignment surgery and related services as a covered benefit and have specific benefit applications and/or limitations for gender reassignment surgery, such specific benefit applications and/or limitations will apply. III. If coverage for gender reassignment surgery is available, it is considered medically necessary when all of the criteria specified in III.A, III.B, III.C, or III.D. are met: A. Criteria for mastectomy and creation of a male chest in female-to-male members: 1. Single letter of referral from a qualified mental health professional (see Policy Guidelines** ***), and 2. Persistent, well-documented gender dysphoria (see Policy Guidelines*); and 3. Capacity to make a fully informed decision and to give consent for treatment; and 4. Age of majority (18 years of age or older); and 5. If significant medical or mental health concerns are present, they must be reasonably well controlled. (NOTE: Hormone therapy is not a pre-requisite.) B. Criteria for breast augmentation (implants/lipofiling) in male-to-female members: 1. Single letter of referral from a qualified mental health professional (see Policy Guidelines** ***), and 2. Persistent, well-documented gender dysphoria (see Policy Guidelines*); and 3. Capacity to make a fully informed decision and to give consent for treatment; and 4. Age of majority (18 years of age or older); and 5. If significant medical or mental health concerns are present, they must be reasonably well controlled. (NOTE: Although not an explicit criterion, it is recommended that male-to-female members undergo feminizing hormone therapy (minimum of 12 months) prior to breast augmentation surgery. The purpose is to maximize breast growth in order to obtain better surgical/aesthetic results.) C. Criteria for gonadectomy (hysterectomy and oophorectomy in female-to-male members and orchiectomy in male-to-female members): 1. Two letters of referral from qualified mental health professionals, one in a purely evaluative role (see Policy Guidelines** ***), and 2. Persistent, well-documented gender dysphoria (see Policy Guidelines*); and 3. Capacity to make a fully informed decision and to give consent for treatment; and

4 4. Age of majority (18 years of age or older); and 5. If significant medical or mental health concerns are present, they must be reasonably well controlled; and 6. Twelve (12) continuous months of hormone therapy as appropriate to the member's gender goals (unless the member has a medical contraindication or is otherwise unable or unwilling to take hormones). (NOTE: The aim of hormone therapy prior to gonadectomy is primarily to introduce a period of reversible estrogen or testosterone suppression, before the member undergoes irreversible surgical intervention.) D. Criteria for genital reconstructive surgery (i.e., any combination of the following: vaginectomy, urethroplasty, metoidioplasty, phalloplasty, scrotoplasty, and implantation of erection and/or testicular prosthesis in female-to-male members; penectomy, vaginoplasty, labiaplasty, vulvoplasty and clitoroplasty in male-to-female members). 1. Two letters of referral from qualified mental health professionals, one in a purely evaluative role (see Policy Guidelines** ***), and 2. Persistent, well-documented gender dysphoria (see Policy Guidelines*); and 3. Capacity to make a fully informed decision and to give consent for treatment; and 4. Age of majority (18 years of age or older); and 5. If significant medical or mental health concerns are present, they must be reasonably well controlled; and 6. Twelve (12) continuous months of hormone therapy as appropriate to the member's gender goals (unless the member has a medical contraindication or is otherwise unable or unwilling to take hormones); and 7. Twelve (12) continuous months of living in a gender role that is congruent with their gender identity (real life experience). (NOTE: Although not an explicit criterion, it is recommended that these members also have regular visits with a mental health or other medical professional.) (NOTE: The above criteria are consistent with The World Professional Association for Transgender Health (WPATH) Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People. (7th Version). 10 ) IV. The following gender reassignment-related surgical procedures are eligible for coverage when the corresponding medical necessity criteria are met: A. Male-to-female: 1. Breast/chest surgery 2. Genital surgery augmentation mammoplasty (implants/lipofiling) penectomy orchiectomy vaginoplasty

5 clitoroplasty labiaplasty vulvoplasty B. Female-to-male: 1. Breast/chest surgery 2. Genital surgery mastectomy (subcutaneous) creation of a male chest hysterectomy oophorectomy urethroplasty metoidioplasty phalloplasty vaginectomy scrotoplasty implantation of erection and/or testicular prosthesis V. Non-genital, non-breast aesthetic surgical procedures are considered cosmetic in nature, even in the presence of a contract benefit for gender reassignment surgery. These include, but may not be limited to, the following: A. Procedures that assist in feminization (male-to-female): reduction thyroid chondroplasty (trachea shave) suction-assisted lipoplasty of the waist rhinoplasty facial feminization surgery / facial bone reduction / jaw shortening / sculpturing face-lift blepharoplasty voice modification surgery (vocal cord shortening) hair reconstruction / hair removal / electrolysis rhytidectomy gluteal augmentation (implants/lipofiling) B. Procedures that assist in masculinization (female-to-male): voice surgery (rare) liposuction (e.g., reduce fat in hips, thighs, and buttocks) pectoral implants chin implants

6 lip reduction Policy Guidelines: (Information to guide medical necessity determination based on the criteria contained within the policy statements above.) * DSM 5 Criteria for Gender Dysphoria in Adults and Adolescents: A. A marked incongruence between one s experienced/expressed gender and assigned gender, of at least 6 months duration, as manifested by two or more of the following indicators: 1. a marked incongruence between one s experienced/expressed gender and primary and/or secondary sex characteristics (or, in young adolescents, the anticipated secondary sex characteristics) 2. a strong desire to be rid of one s primary and/or secondary sex characteristics because of a marked incongruence with one s experienced/expressed gender (or, in young adolescents, a desire to prevent the development of the anticipated secondary sex characteristics) 3. a strong desire for the primary and/or secondary sex characteristics of the other gender 4. a strong desire to be of the other gender (or some alternative gender different from one s assigned gender) 5. a strong desire to be treated as the other gender (or some alternative gender different from one s assigned gender) 6. a strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender different from one s assigned gender) ** Format and content of referral letters for surgery from Qualified Health Professionals: (From WPATH Standards of Care, 7th Version 10 ) 1. The client's general identifying characteristics; and 2. Results of the client's psychosocial assessment, including any diagnoses; and 3. The duration of the mental health professional's relationship with the client, including the type of evaluation and therapy or counseling to date; and 4. An explanation that the criteria for surgery have been met, and a brief description of the clinical rationale for supporting the patient's request for surgery; and 5. A statement about the fact that informed consent has been obtained from the patient; and 6. A statement that the mental health professional is available for coordination of care and welcomes a phone call to establish this. Note: One referral from a qualified mental health professional is needed for breast surgery (e.g., mastectomy). Two referrals from qualified mental health professionals who have independently assessed the patient are needed for genital surgery (i.e.,

7 hysterectomy/salpingo-oophorectomy, orchiectomy, genital reconstructive surgeries). If the first referral is from the patient s psychotherapist, the second referral should be from a person who has only had an evaluative role with the patient. Two separate letters, or one letter signed by both (e.g., if practicing within the same clinic) may be sent. Each referral letter, however, is expected to cover the same topics in the areas outlined above. *** Characteristics of a Qualified Mental Health Professional: (From WPATH Standards of Care, 7th Version 10 ) 1. A master s degree or its equivalent in a clinical behavioral science field. This degree or a more advanced one should be granted by an institution accredited by the appropriate national or regional accrediting board. The mental health professional should also have documented credentials from the relevant licensing board or equivalent; and 2. Competence in using the Diagnostic Statistical Manual of Mental Disorders and/or the International Classification of Diseases for diagnostic purposes; and 3. Ability to recognize and diagnose co-existing mental health concerns and to distinguish these from gender dysphoria; and 4. Knowledgeable about gender nonconforming identities and expressions, and the assessment and treatment of gender dysphoria. 5. Continuing education in the assessment and treatment of gender dysphoria. This may include attending relevant professional meetings, workshops, or seminars; obtaining supervision from a mental health professional with relevant experience; or participating in research related to gender nonconformity and gender dysphoria Supplemental Information: Centers for Medicare and Medicaid Services (CMS): 5,9 According to the National Coverage Determination (NCD) for Transsexual Surgery (140.3), "Because of the lack of well controlled, long term studies of the safety and effectiveness of the surgical procedures and attendant therapies, the treatment is considered experimental. Moreover, there is a high rate of serious complications for these surgical procedures. For these reasons, transsexual surgery is not covered." 5 This NCD has been invalidated effective May 30, (see below) According to Pub Medicare National Coverage Determinations (Transmittal 169), the Department of Health and Human Services Departmental Appeals Board (DAB) has invalidated National Coverage Determination (NCD) Transsexual Surgery pursuant to section 1869(f)(1)(A)(iii) of the Social Security Act (SSA). (Docket #A-13-47, Decision #2576) dated May 30, As a consequence of this decision, NCD is no longer valid effective May 30, Because the NCD is no longer valid as of the effective date, its provisions are no longer a basis for denying claims for Medicare coverage of transsexual surgery under 42 CFR Moreover, any local coverage determinations used to adjudicate such claims may not be based

8 on or rely on the provisions or reasoning from section of Pub , Medicare NCD Manual. In the absence of an NCD, contractors and adjudicators should consider whether any Medicare claims for these services are reasonable and necessary under 1862(a)(1)(A) of the SSA consistent with the existing guidance for making such decisions when there is no NCD. 9 For further details, please go to: Guidance/Guidance/Transmittals/2014-Transmittals-Items/R169NCD.html] Horizon BCBSNJ Medical Policy Development Process: This Horizon BCBSNJ Medical Policy (the Medical Policy ) has been developed by Horizon BCBSNJ s Medical Policy Committee (the Committee ) consistent with generally accepted standards of medical practice, and reflects Horizon BCBSNJ s view of the subject health care services, supplies or procedures, and in what circumstances they are deemed to be medically necessary or experimental/ investigational in nature. This Medical Policy also considers whether and to what degree the subject health care services, supplies or procedures are clinically appropriate, in terms of type, frequency, extent, site and duration and if they are considered effective for the illnesses, injuries or diseases discussed. Where relevant, this Medical Policy considers whether the subject health care services, supplies or procedures are being requested primarily for the convenience of the covered person or the health care provider. It may also consider whether the services, supplies or procedures are more costly than an alternative service or sequence of services, supplies or procedures that are at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the relevant illness, injury or disease. In reaching its conclusion regarding what it considers to be the generally accepted standards of medical practice, the Committee reviews and considers the following: all credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, physician and health care provider specialty society recommendations, the views of physicians and health care providers practicing in relevant clinical areas (including, but not limited to, the prevailing opinion within the appropriate specialty) and any other relevant factor as determined by applicable State and Federal laws and regulations. Index: Gender Dysphoria References: 1. The World Professional Association for Transgender Health (WPATH), formerly known as the Harry Benjamin International Gender Dysphoria Associaion, HBIGDA). Standards of Care for Gender Identity Disorders, Sixth Version. February, Available at: (last accessed 03/25/2010) 2. Hembree WC, Cohen-Kettenis P, et al; Endocrine Society. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guidelines. J Clin Endocrinol Metab Sep;94(9): Epub 2009 Jun 9. Available at: (current version as of 08/08/2015) 3. Day P. Tech Brief Series. Trans-gender Reassignment Surgery. New Zealand Health Technology Assessment (NZHTA) Report 2002;1(1). 4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. (DSM-IV-TR)

9 5. Centers for Medicare and Medicaid Services (CMS). NCD for Transsexual Surgery (140.3). Available at: 40%2E3%3A1%3ATranssexual+Surgery. 6. ECRI Institute s Health Technology Assessment Information Service (HTAIS). Hotline Response: Sexual Reassignment for Gender Identity Disorders. Updated: 12/30/2009. (last accessed 04/05/2010) 7. Byne W, Bradley SJ, Eyler AE et al. Report of the American Psychiatric Association Task Force on Treatment of Gender Identity Disorder. Arch Sex Behav Aug;41(4): American Psychiatric Association. Gender Dysphoria - explanation of replacing "disorder" with "dysphoria" in DSM 5. Available at: 9. CMS Manual System. Pub Medicare National Coverage Determination (Transmittal 169). Subject: Invalidation of National Coverage Determination Transsexual Surgery. Effective date: May 30, Available at: Guidance/Guidance/Transmittals/2014-Transmittals-Items/R169NCD.html 10. The World Professional Association for Transgender Health (WPATH). Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People. 7th Version Available at: %202011%20WPATH.pdf Codes: (The list of codes is not intended to be all-inclusive and is included below for informational purposes only. Inclusion or exclusion of a procedure, diagnosis, drug or device code(s) does not constitute or imply authorization, certification, approval, offer of coverage or guarantee of payment.) CPT* HCPCS * CPT only copyright 2016 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Medical policies can be highly technical and are designed for use by the Horizon BCBSNJ professional staff in making coverage determinations. Members referring to this policy should discuss it with their treating physician, and should refer to their specific benefit plan for the terms, conditions, limitations and exclusions of their coverage. The Horizon BCBSNJ Medical Policy Manual is proprietary. It is to be used only as authorized by Horizon BCBSNJ and its affiliates. The contents of this Medical Policy are not to be copied, reproduced or circulated to other parties

10 without the express written consent of Horizon BCBSNJ. The contents of this Medical Policy may be updated or changed without notice, unless otherwise required by law and/or regulation. However, benefit determinations are made in the context of medical policies existing at the time of the decision and are not subject to later revision as the result of a change in medical policy

Please note that this should only be used for feedback and comments specifically related to this particular medical policy.

Please note that this  should only be used for feedback and comments specifically related to this particular medical policy. E-Mail Us Close Please note that this email should only be used for feedback and comments specifically related to this particular medical policy. Horizon BCBSNJ Uniform Medical Policy Manual Section: Surgery

More information

MEDICAL POLICY No R1 GENDER REASSIGNMENT SURGERY

MEDICAL POLICY No R1 GENDER REASSIGNMENT SURGERY GENDER REASSIGNMENT SURGERY Effective Date: January 1, 2017* Review Dates: 8/15, 8/16, 11/16 Date Of Origin: August 12, 2015 Status: Current *Note: For fully funded commercial (individual or group), this

More information

Transgender: A broad spectrum of individuals who transiently or persistently identify with a gender different from their natal gender.

Transgender: A broad spectrum of individuals who transiently or persistently identify with a gender different from their natal gender. POLICY TITLE: Gender Reassignment Surgery POLICY STATEMENT: Gender reassignment surgery is one treatment option for extreme cases of Gender Dysphoria Disorder. Gender dysphoria disorder (formerly termed

More information

Values Accountability Integrity Service Excellence Innovation Collaboration

Values Accountability Integrity Service Excellence Innovation Collaboration n05586 Transgender and Gender Dysphoria /Gender Incongruence Services Values Accountability Integrity Service Excellence Innovation Collaboration Abstract Purpose: Network Health Plan/Network Health Insurance

More information

Transgender Medical Benefits

Transgender Medical Benefits Transgender Medical Benefits The following Transgender Medical Benefits are based on the Standards of Care published by the World Professional Association for Transgender Health (WPATH). All transgender

More information

Medical Necessity Guidelines: Transgender Surgical Procedures

Medical Necessity Guidelines: Transgender Surgical Procedures Medical Necessity Guidelines: Transgender Surgical Procedures Effective: September 13, 2017 Clinical Documentation and Prior Authorization Required Applies to: Coverage Guideline, No Prior Authorization

More information

Protocol. Gender Reassignment Surgery

Protocol. Gender Reassignment Surgery Protocol Gender Reassignment Surgery Medical Benefit Effective Date: 07/01/18 Next Review Date: 03/19 Preauthorization Yes Review Dates: 03/15, 03/16, 03/17, 03/18, 05/18 Preauthorization is required.

More information

Division: Medical Management Department: Utilization Management

Division: Medical Management Department: Utilization Management Retired Date: Page 1 of 1 1. POLICY DESCRIPTION: Gender Reassignment Surgery 2. RESPONSIBLE PARTIES: Medical Management Administration, Utilization Management, Integrated Care Management, Pharmacy, Claims

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Gender Confirmation Surgery and Hormone Therapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: gender_confirmation_surgery_and_hormone_therapy 7/2011 5/2018

More information

NHS MEDICAL POLICY. Transgender Surgical Procedures Procedure

NHS MEDICAL POLICY. Transgender Surgical Procedures Procedure Effective Date: 12/13/2017 NHS MEDICAL POLICY Transgender Surgical Procedures Procedure 2017-003 Transgender surgical procedures may be indicated when ALL of the following are present: 1 The member is

More information

Medical Policy. Transgender Reassignment Surgery. Policy Number: Policy History

Medical Policy. Transgender Reassignment Surgery. Policy Number: Policy History Policy Number: 1069 Policy History Approve Date: 06/01/2018 Effective Date: 06/01/2018 Preauthorization All Plans Benefit plans vary in coverage and some plans may not provide coverage for certain service(s)

More information

Coding... 4 Benefit Application... 6 Description of Services... 7 Clinical Evidence... 8

Coding... 4 Benefit Application... 6 Description of Services... 7 Clinical Evidence... 8 Title: TABLE OF CONTENTS Product Variations.... 1 Policy Statement.... 1 Related Policies.... 3 Policy Guidelines..... 3 Coding.... 4 Benefit Application........ 6 Description of Services..... 7 Clinical

More information

PROVIDER POLICIES & PROCEDURES

PROVIDER POLICIES & PROCEDURES PROVIDER POLICIES & PROCEDURES GENDER REASSIGNMENT SURGERY The primary purpose of this policy is to assist providers enrolled in the Connecticut Medical Assistance Program (CMAP) with the information needed

More information

Transgender Services Corporate Medical Policy

Transgender Services Corporate Medical Policy Transgender Services Corporate Medical Policy File name: Transgender Services File Code: UM.SURG.06 Origination: 5/30/2011 Last Review: 06/2017 Next Review: 06/2018 Effective Date: 09/01/2017 Policy Coding

More information

JOHNS HOPKINS HEALTHCARE

JOHNS HOPKINS HEALTHCARE Page 1 of 10 ACTION: New Effective Date: 09/05/2014 Revising : Review Dates: 06/02/17 Superseding Archiving Retiring Johns Hopkins HealthCare LLC (JHHC) provides a full spectrum of health care products

More information

POLICIES AND PROCEDURE MANUAL

POLICIES AND PROCEDURE MANUAL POLICIES AND PROCEDURE MANUAL Policy: MP307 Section: Medical Benefit Policy Subject: Gender Dysphoria and Gender Confirmation Treatment I. Policy: Gender Dysphoria and Gender Confirmation Treatment II.

More information

Medi-Cal, Healthy Workers, Healthy Kids

Medi-Cal, Healthy Workers, Healthy Kids Disclaimer: Criteria may change as the state and Medi-Cal update current regulations for transgender services Department Owner: Lines of Business Affected: Utilization Management Medi-Cal, Healthy Workers,

More information

Gender Confirming Surgery

Gender Confirming Surgery Gender Confirming Surgery Policy Number: 2018M0202A Effective Date: 5/14/2018 Review Date: 5/14/2018 Next Review Date: 5/14/2020 Important Information - Please Read Before Using This Policy UCare has developed

More information

Gender Identity Services

Gender Identity Services Gender Identity Services I. Policy University Health Alliance (UHA) will cover Gender Identity Services when such services meet the medical criteria guidelines (subject to limitations and exclusions) indicated

More information

Harold Husovsky, MD. Associate Professor of General Medicine at SUNY Health Science Center

Harold Husovsky, MD. Associate Professor of General Medicine at SUNY Health Science Center Harold Husovsky, MD Associate Professor of General Medicine at SUNY Health Science Center Care of the Transgendered Syracuse University, 1/09/07 Goals Introductions Definitions Statistics Evaluation Treatments

More information

Clinical Policy: Gender Reassignment Surgery Reference Number: CA.CP.MP.95

Clinical Policy: Gender Reassignment Surgery Reference Number: CA.CP.MP.95 Clinical Policy: Reference Number: CA.CP.MP.95 Effective Date: 6/1/2017 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Clinical Policy: Gender Reassignment Surgery

Clinical Policy: Gender Reassignment Surgery Clinical Policy: Reference Number: CP.MP.95 Last Review Date: 10/18 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description

More information

Trans Affirming Letter Writing: Best Practices and Challenges for BHP. Justin Wheeler, LISW-S Michelle Pride, Ph.D.

Trans Affirming Letter Writing: Best Practices and Challenges for BHP. Justin Wheeler, LISW-S Michelle Pride, Ph.D. Trans Affirming Letter Writing: Best Practices and Challenges for BHP Justin Wheeler, LISW-S Michelle Pride, Ph.D. Disclosures The speakers and members of the planning committee do not have a conflict

More information

MEDICAL TREATMENTS OF GENDER DYSPHORIA

MEDICAL TREATMENTS OF GENDER DYSPHORIA Medical Policy MP 2.01.501 Last Review: 01/30/2018 Effective Date: 01/30/2018 Section: Medicine Related Policies 5.01.501 Guidelines for Prior Authorization of Pharmacologic Therapies 5.01.23 Testosterone

More information

IMPORTANT REMINDER DESCRIPTION

IMPORTANT REMINDER DESCRIPTION Medical Policy Manual Medicine, Policy No. 153 Transgender Services Next Review: September 2018 Last Review: November 2017 Effective: April 1, 2018 IMPORTANT REMINDER Medical Policies are developed to

More information

Cigna Medical Coverage Policy

Cigna Medical Coverage Policy Cigna Medical Coverage Policy Subject Gender Reassignment Surgery Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 7 References... 10 Effective Date... 3/15/2016

More information

GENDER DYSPHORIA. Guideline Number: BH727GD_ Effective Date: October, 2017

GENDER DYSPHORIA. Guideline Number: BH727GD_ Effective Date: October, 2017 GENDER DYSPHORIA Optum Coverage Determination Guideline Guideline Number: BH727GD_102017 Effective Date: October, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS... 1 COVERAGE

More information

Position Statement on Medical Necessity of Treatment, Sex Reassignment, and Insurance Coverage in the U.S.A.

Position Statement on Medical Necessity of Treatment, Sex Reassignment, and Insurance Coverage in the U.S.A. 21 December 2016 Position Statement on Medical Necessity of Treatment, Sex Reassignment, and Insurance Coverage in the U.S.A. The World Professional Association for Transgender Health (WPATH) is an international,

More information

Treatment of Gender Dysphoria

Treatment of Gender Dysphoria Medical Coverage Policy Treatment of Gender Dysphoria Table of Contents Effective Date...12/15/2017 Next Review Date... 3/15/2018 Coverage Policy Number... 0266 Related Coverage Resources Coverage Policy...

More information

Gender Identity Services

Gender Identity Services Gender Identity Services www.sandyford.org 2 Contents Welcome to Sandyford....... 4 The Gender Identity Clinic...... 4 Treatment Options for Transsexual Women Male to Female (MTF)........ 6 Treatment Options

More information

Clinical Policy: Gender Reassignment Surgery Reference Number: CP.MP.HN 496

Clinical Policy: Gender Reassignment Surgery Reference Number: CP.MP.HN 496 Clinical Policy: Reference Number: CP.MP.HN 496 Effective Date: 11/09 Last Review Date: 1/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

THE YEAR IN REVIEW: SURGERY. Marta Bizic Faculty of Medicine, University of Belgrade, Serbia Belgrade Center for Genital Reconstructive Surgery

THE YEAR IN REVIEW: SURGERY. Marta Bizic Faculty of Medicine, University of Belgrade, Serbia Belgrade Center for Genital Reconstructive Surgery THE YEAR IN REVIEW: SURGERY Marta Bizic Faculty of Medicine, University of Belgrade, Serbia Belgrade Center for Genital Reconstructive Surgery Conflict of interest I have no potential conflict of interest

More information

Clinical Policy: Gender Confirmation Surgery Reference Number: PA.CP.MP.95

Clinical Policy: Gender Confirmation Surgery Reference Number: PA.CP.MP.95 Clinical Policy: Reference Number: PA.CP.MP.95 Effective Date: 01/18 Last Review Date: 09/17 Coding Implications Revision Log Services for gender confirmation most often include hormone treatment, counseling,

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Pellet (Testopel) Reference Number: CP.PHAR.354 Effective Date: 08.01.17 Last Review Date: 11.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the

More information

All service users will benefit from having the information on these forms. The consent forms may be read in conjunction with the NHS booklet

All service users will benefit from having the information on these forms. The consent forms may be read in conjunction with the NHS booklet INFORMED CONSENT FORMS The following forms are intended to protect both service users and clinicians by ensuring that proper information has been given to service users, and that this is fully understood,

More information

A Guide to Hormone Therapy for Trans People available at

A Guide to Hormone Therapy for Trans People available at INFORMED CONSENT FORMS The following forms are intended to protect both service users and clinicians by ensuring that proper information has been given to service users, and that this is fully understood,

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Gender Transition Services MP-033-MD-DE Medical Management Provider Notice Date: 01/15/2018 Issue Date: 02/15/2018 Effective

More information

Clinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: 03.01.12 Last Review Date: 02.19 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of

More information

Determining a Client s Readiness for Gender Transition:

Determining a Client s Readiness for Gender Transition: Determining a Client s Readiness for Gender Transition: Clinical Evaluation and Recommendation VARUNEE FAII SANGGANJANAVANICH, PHD, LPCC-S THE UNIVERSITY OF AKRON Session Overview Identify DSM 5 diagnostic

More information

GENDER DYSPHORIA TREATMENT

GENDER DYSPHORIA TREATMENT GENDER DYSPHORIA TREATMENT Protocol: SUR053 Effective Date: January 1, 2019 Table of Contents Page BENEFIT CONSIDERATIONS... 1 COVERAGE RATIONALE... 2 DEFINITIONS... 4 APPLICABLE CODES... 5 DESCRIPTION

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Thyrogen) Reference Number: CP.PHAR.95 Effective Date: 03.12 Last Review Date: 08.18 Line of Business: Medicaid, HIM-Medical Benefit Revision Log See Important Reminder at the end of

More information

Clinical Policy: Digital Breast Tomosynthesis Reference Number: CP.MP.90

Clinical Policy: Digital Breast Tomosynthesis Reference Number: CP.MP.90 Clinical Policy: Reference Number: CP.MP.90 Effective Date: 01/18 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Medical Policy Transgender Health Services

Medical Policy Transgender Health Services Medical Policy Transgender Health Services Subject: Transgender Health Services Background: Transgender health services, which can involve various reconstruction surgeries, are part of the treatment approach

More information

Clinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: 03.01.12 Last Review Date: 02.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of

More information

Clinical Policy: Essure Removal Reference Number: CP.MP.131

Clinical Policy: Essure Removal Reference Number: CP.MP.131 Clinical Policy: Reference Number: CP.MP.131 Effective Date: 11/16 Last Review Date: 11/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: DNA Analysis of Stool to Screen for Colorectal Cancer

Clinical Policy: DNA Analysis of Stool to Screen for Colorectal Cancer Clinical Policy: to Screen for Colorectal Cancer Reference Number: CP.MP.125 Last Review Date: 07/18 See Important Reminder at the end of this policy for important regulatory and legal information. Coding

More information

Clinical Policy: Cochlear Implant Replacements Reference Number: CP.MP.14

Clinical Policy: Cochlear Implant Replacements Reference Number: CP.MP.14 Clinical Policy: Reference Number: CP.MP.14 Effective Date: 02/09 Last Review Date: 09/17 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory and

More information

Implantable Hormone Pellets

Implantable Hormone Pellets Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

NOTE: This policy is not effective until January 1, 2015.

NOTE: This policy is not effective until January 1, 2015. Medical Policy Manual Topic: Transgender Services Date of Origin: September 2014 Section: Medicine Last Reviewed Date: September 2014 Policy No: 153 Effective Date: January 1, 2015 NOTE: This policy is

More information

Clinical Policy: Implantable Miniature Telescope for Age Related Macular Degeneration Reference Number: CP.MP.517

Clinical Policy: Implantable Miniature Telescope for Age Related Macular Degeneration Reference Number: CP.MP.517 Clinical Policy: Implantable Miniature Telescope for Age Related Macular Reference Number: CP.MP.517 Effective Date: 11/16 Last Review Date: 11/17 See Important Reminder at the end of this policy for important

More information

Clinical Policy: Multiple Sleep Latency Testing

Clinical Policy: Multiple Sleep Latency Testing Clinical Policy: Reference Number: CP.MP.24 Last Review Date: 04/18 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description

More information

Gender Identity Services

Gender Identity Services Gender Identity Services Policy Number: Original Effective Date: MM.06.026 01/01/2016 Line(s) of Business: Current Effective Date: Fed 87; HMO; PPO; 01/01/2017 QUEST Integration Section: Medicine Place(s)

More information

Clinical Policy: Cochlear Implant Replacements

Clinical Policy: Cochlear Implant Replacements Clinical Policy: Reference Number: CP.MP.14 Last Review Date: 07/18 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory and legal information. Description

More information

Lumify. Lumify reimbursement guide {D DOCX / 1

Lumify. Lumify reimbursement guide {D DOCX / 1 Lumify Lumify reimbursement guide {D0672917.DOCX / 1 {D0672917.DOCX / 1 } Contents Overview 4 How claims are paid 4 Documentation requirements 5 Billing codes for ultrasound: Non-hospital setting 6 Billing

More information

Medical Review Criteria Transgender Health Services

Medical Review Criteria Transgender Health Services Medical Review Criteria Transgender Health Services Subject: Transgender Health Services Background: Transgender health services, which can involve various reconstruction surgeries, are part of the treatment

More information

GENder Education and Care Interdisciplinary Support (GENECIS) Feminizing Medications for Patients with Gender Dysphoria

GENder Education and Care Interdisciplinary Support (GENECIS) Feminizing Medications for Patients with Gender Dysphoria GENder Education and Care Interdisciplinary Support (GENECIS) Feminizing Medications for Patients with Gender Dysphoria Patient Information and Informed Consent and Assent for Minors Before using medications

More information

Gender Reassignment Surgery COMMERCIAL AND MEDICARE

Gender Reassignment Surgery COMMERCIAL AND MEDICARE COMMERCIAL AND MEDICARE Last Review Date: June 20, 2012 Number: MG.MM.SU.28c Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider

More information

Organic. TransSEXualism has nothing to do with sex but everything with gender identity... (NATURE) Psychological (NURTURE)

Organic. TransSEXualism has nothing to do with sex but everything with gender identity... (NATURE) Psychological (NURTURE) University Hospital Ghent (Belgium) TRANSGENDER CARE introduction TransSEXualism has nothing to do with sex but everything with gender identity... Stan Monstrey Gender dysphoria Gender Identity Disorder

More information

Clinical Policy: Thryoid Hormones and Insulin Testing in Pediatrics Reference Number: CP.MP.154

Clinical Policy: Thryoid Hormones and Insulin Testing in Pediatrics Reference Number: CP.MP.154 Clinical Policy: Thryoid Hormones and Insulin Testing in Pediatrics Reference Number: CP.MP.154 Effective Date: 12/17 Last Review Date: 12/17 See Important Reminder at the end of this policy for important

More information

The Monash Gender Dysphoria Clinic aims to assist clients experiencing Gender Dysphoria through:

The Monash Gender Dysphoria Clinic aims to assist clients experiencing Gender Dysphoria through: Gender Dysphoria Clinic 352 South Road Hampton East VIC 3188 Tel: (03) 9556 5216 (Tuesday & Wednesday ONLY) Fax: (03) 9556 5256 Email: genderclinic@monashhealth.org Web: www.monashhealth.org/page/gender_dysphoria

More information

Clinical Policy: Pasireotide (Signifor LAR) Reference Number: CP.PHAR.332 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Pasireotide (Signifor LAR) Reference Number: CP.PHAR.332 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Signifor LAR) Reference Number: CP.PHAR.332 Effective Date: 03.01.17 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the

More information

Clinical Policy: Fecal Calprotectin Assay Reference Number: CP.MP.135

Clinical Policy: Fecal Calprotectin Assay Reference Number: CP.MP.135 Clinical Policy: Reference Number: CP.MP.135 Effective Date: 11/16 Last Review Date: 11/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

-There are 2 aspects of sex: genetic sex and anatomical sex. In women, the sex chromosomes are XX. In men, the sex chromosomes are XY.

-There are 2 aspects of sex: genetic sex and anatomical sex. In women, the sex chromosomes are XX. In men, the sex chromosomes are XY. 111 Chapter 7 Gender Sex vs. Gender sex -refers to biological maleness or femaleness -There are 2 aspects of sex: genetic sex and anatomical sex 1. genetic sex -determined by the sex chromosomes In women,

More information

Clinical Policy: Implantable Hormone Pellets Reference Number: CA.CP.MP.507

Clinical Policy: Implantable Hormone Pellets Reference Number: CA.CP.MP.507 Clinical Policy: Reference Number: CA.CP.MP.507 Effective Date: 1/12 Last Review Date: 7/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

HARRY BENJAMIN INTERNATIONAL GENDER DYSPHORIA ASSOCIATION'S. THE STANDARDS OF CARE FOR GENDER IDENTITY DISORDERS (Fifth Version)

HARRY BENJAMIN INTERNATIONAL GENDER DYSPHORIA ASSOCIATION'S. THE STANDARDS OF CARE FOR GENDER IDENTITY DISORDERS (Fifth Version) The Standards of Care are also available in Adobe Acrobat (*.pdf) format. You can download the Adobe Acrobat reader by selecting this link: Download Acrobat. HARRY BENJAMIN INTERNATIONAL GENDER DYSPHORIA

More information

Information About Hormonal Treatment for Trans men

Information About Hormonal Treatment for Trans men Information About Hormonal Treatment for Trans men Leighton J Seal PhD FRCP Consultant Endocrinologist, Gender Identity Clinic, (Charing Cross) West London Mental Health NHS Trust 12/12/2016 Introduction...

More information

Clinical Policy: Cinacalcet (Sensipar) Reference Number: CP.PHAR.61 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Cinacalcet (Sensipar) Reference Number: CP.PHAR.61 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Sensipar) Reference Number: CP.PHAR.61 Effective Date: 05.01.11 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Radial Head Implant Reference Number: CP.MP.148

Clinical Policy: Radial Head Implant Reference Number: CP.MP.148 Clinical Policy: Reference Number: CP.MP.148 Effective Date: 08/17 Last Review Date: 08/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Trigger Point Injections for Pain Management

Clinical Policy: Trigger Point Injections for Pain Management Clinical Policy: for Pain Management Reference Number: CP.MP.169 Last Review Date: 08/18 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications

More information

Clinical Policy: Robotic Surgery Reference Number: CP.MP. 207

Clinical Policy: Robotic Surgery Reference Number: CP.MP. 207 Clinical Policy: Robotic Surgery Reference Number: CP.MP. 207 Effective Date: 03/05 Last Review Date: 10/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important

More information

Disclosures. Endocrine Care of the Transgender Patient. Objectives. Start where you are. Use what you have. Do what you can. Vocabulary.

Disclosures. Endocrine Care of the Transgender Patient. Objectives. Start where you are. Use what you have. Do what you can. Vocabulary. Disclosures Endocrine Care of the Transgender Patient Kathryn Tierney, MSN, APRN, FNP-BC Medical Director, Middlesex Hospital Transgender Medicine Program Middlesex Multispecialty Group Division of Endocrinology

More information

Guidelines for the Clinical Care of Persons with Gender Dysphoria

Guidelines for the Clinical Care of Persons with Gender Dysphoria Guidelines for the Clinical Care of Persons with Gender Dysphoria Friday, May 27, 2016 2:15 5:00 PM 25 th Annual Scientific and Clinical Congress American Association of Clinical Endocrinologist Orlando,

More information

Medical Necessity Guidelines: Applied Behavioral Analysis (ABA) including Early Intervention for RITogether

Medical Necessity Guidelines: Applied Behavioral Analysis (ABA) including Early Intervention for RITogether Medical Necessity Guidelines: Applied Behavioral Analysis (ABA) including Effective: August 1, 2017 Clinical Documentation and Prior Authorization Required Applies to: Coverage Guideline, No prior Authorization

More information

Surgical Treatment of Bilateral Gynecomastia

Surgical Treatment of Bilateral Gynecomastia Surgical Treatment of Bilateral Gynecomastia Policy Number: 7.01.13 Last Review: 4/2018 Origination: 4/2006 Next Review: 4/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Kadcyla) Reference Number: CP.PHAR.229 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: Commercial, HIM-Medical Benefit, Medicaid Coding Implications Revision Log See

More information

Clinical Policy: Total Artificial Heart Reference Number: CP.MP.127

Clinical Policy: Total Artificial Heart Reference Number: CP.MP.127 Clinical Policy: Reference Number: CP.MP.127 Effective Date: 12/16 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18 Clinical Policy: Reference Number: CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: No Coverage Criteria/Off-Label Use Policy Reference Number: CP.PMN.53 Effective Date: 07.01.18 Last Review Date: 05.01.18 Line of Business: Oregon Health Plan Revision Log See Important

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: LA.PPA.12 Effective Date: 02/11 Last Review Date: 01/18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this policy for

More information

Specialised Services Policy: CP 44 Body Contouring

Specialised Services Policy: CP 44 Body Contouring Specialised Services Policy: CP 44 Body Contouring Document Author: Specialised Planner Executive Lead: Director of Planning Approved by: Management Group Issue Date: 11 July 2013 Review Date: 01 July

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Ibrance) Reference Number: CP.PHAR.125 Effective Date: 10.01.15 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

Applied Behavior Analysis for Autism Spectrum Disorders

Applied Behavior Analysis for Autism Spectrum Disorders Applied Behavior Analysis for Autism Spectrum Disorders I. Policy University Health Alliance (UHA) will reimburse for Applied Behavioral Analysis (ABA), as required in relevant State of Hawaii mandates,

More information

Clinical Policy: Gastric Electrical Stimulation Reference Number: CP.MP.40

Clinical Policy: Gastric Electrical Stimulation Reference Number: CP.MP.40 Clinical Policy: Reference Number: CP.MP.40 Effective Date: 09/09 Last Review Date: 10/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: EEG in the Evaluation of Headache Reference Number: CP.MP.155

Clinical Policy: EEG in the Evaluation of Headache Reference Number: CP.MP.155 Clinical Policy: EEG in the Evaluation of Headache Reference Number: CP.MP.155 Effective Date: 12/17 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy

More information

Clinical Policy: Levetiracetam (Spritam) Reference Number: CP.CPA.156 Effective Date: Last Review Date: 11.18

Clinical Policy: Levetiracetam (Spritam) Reference Number: CP.CPA.156 Effective Date: Last Review Date: 11.18 Clinical Policy: (Spritam) Reference Number: CP.CPA.156 Effective Date: 11.16.16 Last Review Date: 11.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

Endocrinology and the Transgender Patient

Endocrinology and the Transgender Patient Endocrinology and the Transgender Patient Matthew Leinung MD Professor of Medicine Albany Medical College This project is supported by the Health Resources and Services Administration (HRSA) of the U.S.

More information

Clinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: CP.MP.145

Clinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: CP.MP.145 Clinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: CP.MP.145 Effective Date: 05/17 Last Review Date: 06/17 See Important Reminder at the end of this policy for important regulatory

More information

FDA Approved Indication(s) Firmagon is indicated for treatment of advanced prostate cancer.

FDA Approved Indication(s) Firmagon is indicated for treatment of advanced prostate cancer. Clinical Policy: (Firmagon) Reference Number: CP.PHAR.170 Effective Date: 10.01.16 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end

More information

Inspire Medical Systems. Physician Billing Guide

Inspire Medical Systems. Physician Billing Guide Inspire Medical Systems Physician Billing Guide 2019 Inspire Medical Systems Physician Billing Guide This Physician Billing Guide was developed to help providers correctly bill for Inspire Upper Airway

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Vraylar) Reference Number: CP.PMN.91 Effective Date: 11.16.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 02/16

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 02/16 Clinical Policy: (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 02/16 Last Review Date: 02/17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY Policy Name: Policy Number: Approved By: CLINICAL MEDICAL POLICY Gender Transition Services MP-033-MD-PA Provider Notice Date: 12/1/2016 Original Effective Date: 1/1/2017 Annual Approval Date: 7/18/2017

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: AZ.CP.PHAR.10.11.8 Effective Date: 07.2016 Last Review Date: 09.12.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this policy

More information

Clinical Policy: Mifepristone (Korlym) Reference Number: CP.PHAR.101

Clinical Policy: Mifepristone (Korlym) Reference Number: CP.PHAR.101 Clinical Policy: (Korlym) Reference Number: CP.PHAR.101 Effective Date: 05/12 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Removing the Constraints to Coverage of Gender-Confirming Healthcare by State Medicaid Programs

Removing the Constraints to Coverage of Gender-Confirming Healthcare by State Medicaid Programs Removing the Constraints to Coverage of Gender-Confirming Healthcare by State Medicaid Programs Nicole M. True ABSTRACT: In April of 2010, the United States Tax Court in O Donnabhain v. Commissioner held

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Policy Reference Number: CP.PMN.53 Effective Date: 09.12.17 Last Review Date: 11.18 Line of Business: Medicaid, HIM-Medical Benefit Revision Log See Important Reminder at the end of this

More information

Foundational funding sources allow BCCHP to screen and diagnose women outside of the CDC guidelines under specific circumstances in Washington State.

Foundational funding sources allow BCCHP to screen and diagnose women outside of the CDC guidelines under specific circumstances in Washington State. Program Description The Breast, Cervical and Colon Health Program (BCCHP) screens qualifying clients for breast cancer. The program is funded through a grant from the Centers for Disease Control and Prevention

More information